Statistics for First Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)
Total visits
| views | |
|---|---|
| First Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc) | 0 |
Total visits per month
| views | |
|---|---|
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |